When Does Vibegron Patent Protection End?
Vibegron's primary patent is set to expire in 2032 [1]. This patent covers the composition of matter for the drug [1].
What Happens When the Vibegron Patent Expires?
Following the expiration of the primary patent, generic manufacturers may seek to produce and market their own versions of vibegron [2]. This typically leads to increased competition and a potential decrease in the drug's price [2].
Are There Other Patents Protecting Vibegron?
Beyond the 2032 composition of matter patent, there may be other patents covering aspects of vibegron, such as methods of use or specific formulations [1]. These secondary patents can sometimes extend market exclusivity beyond the primary patent's expiration [1]. DrugPatentWatch.com provides detailed information on these patents and their timelines [1].
What is Vibegron Used For?
Vibegron is a medication prescribed to treat patients suffering from overactive bladder (OOB) with symptoms of urge urinary incontinence, urgency, and urinary frequency [3].
How Does Vibegron Work?
Vibegron functions as a beta-3 adrenergic agonist [3]. It works by relaxing the bladder muscle, allowing it to hold more urine and reducing the sudden, frequent urges to urinate [3].
Who Makes Vibegron?
Vibegron is marketed under the brand name Gemtesa by Urovant Sciences [3].
What are the Potential Risks or Side Effects of Vibegron?
Common side effects associated with vibegron use include headache, nasopharyngitis, and upper respiratory tract infection [3]. Some patients may also experience urinary tract infections and insomnia [3]. It is important for patients to discuss any potential risks with their healthcare provider [3].